Patents by Inventor Tim Sproul

Tim Sproul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF
    Publication number: 20170058031
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Inventors: David John King, Alison WITTE, Heidi N. LEBLANC, Richard THEOLIS, Asna MASOOD, Mark YAMANAKA, Kyra D. ZENS, Sarah R. REED, Tim SPROUL, Chetana RAO-NAIK, David Passmore, Dawn M. TANAMACHI, Kristopher TOY
  • Human antibodies that bind CD22 and uses thereof
    Patent number: 9499632
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: November 22, 2016
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: David John King, Alison Witte, Heidi N. Leblanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
  • HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF
    Publication number: 20130230530
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Application
    Filed: February 20, 2013
    Publication date: September 5, 2013
    Applicant: Medarex, Inc.
    Inventors: David John King, Alison Witte, Heidi N. Leblanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
  • Human antibodies that bind CD22 and uses thereof
    Patent number: 8481683
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: July 9, 2013
    Assignee: Medarex, Inc.
    Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
  • Human Antibodies That Bind Cd22 And Uses Thereof
    Publication number: 20100143368
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Application
    Filed: November 30, 2007
    Publication date: June 10, 2010
    Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Emory, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore